Nilsson, M. B., Giri, U., Gudikote, J., Tang, X., Lu, W., Tran, H., . . . Heymach, J. V. (2015). KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib. Clin Cancer Res.
Chicago Stili AlıntıNilsson, Monique B., et al. "KDR Amplification Is Associated With VEGF-Induced Activation of the MTOR and Invasion Pathways but Does Not Predict Clinical Benefit to the VEGFR TKI Vandetanib." Clin Cancer Res 2015.
MLA AlıntıNilsson, Monique B., et al. "KDR Amplification Is Associated With VEGF-Induced Activation of the MTOR and Invasion Pathways but Does Not Predict Clinical Benefit to the VEGFR TKI Vandetanib." Clin Cancer Res 2015.
Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..